PART I Item 1. B usiness. Overv iew We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients. Our products are developed with customized and evolved adeno-associated virus (AAV) vectors invented from our proprietary vector discovery platform, Therapeutic Vector Evolution (TVE) which was designed to generate vectors with properties that overcome the limit...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001193125-26-114075 | EDGAR | 98K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-030056 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023183 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0000950170-23-008142 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004794 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015502 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-273343 | EDGAR | 72K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106244 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067040 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126370 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094010 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056933 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062103 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040661 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020703 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023185 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016882 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009702 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-131739 | EDGAR | 1K words |
| 2026-03-18 | 0001193125-26-113949 | EDGAR | — |
| 2026-01-26 | 0001193125-26-022559 | EDGAR | — |
| 2026-01-07 | 0001193125-26-005470 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314167 | EDGAR | — |
| 2025-11-17 | 0001193125-25-283861 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273340 | EDGAR | — |
| 2025-11-07 | 0001193125-25-272286 | EDGAR | — |
| 2025-11-06 | 0001193125-25-267934 | EDGAR | — |
| 2025-10-31 | 0001193125-25-259302 | EDGAR | — |
100 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001650648 |
| Ticker | FDMT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.4dmoleculartherapeutics.com |
| Listed | 2020-12-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report